We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+25.17%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$14.8B
AUM Growth
+$1.58B
Cap. Flow
-$1.22B
Cap. Flow %
-8.22%
Top 10 Hldgs %
44.34%
Holding
132
New
32
Increased
38
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$317M
2
CRM icon
Salesforce
CRM
+$270M
3
TMO icon
Thermo Fisher Scientific
TMO
+$259M
4
MDCO
Medicines Co
MDCO
+$221M
5
PPLI
People Inc
PPLI
+$137M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.55B
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$754M
3
AABA
Altaba Inc
AABA
+$666M
4
BABA icon
Alibaba
BABA
+$196M
5
CTXS
Citrix Systems Inc
CTXS
+$183M

Sector Composition

Rank Sector Weight
1 Healthcare 46.6%
2 Communication Services 12.82%
3 Technology 9.97%
4 Industrials 5.05%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
51
Kyntra Bio
KYNB
$30.4M
$57.9M 0.39%
54,000
+14,000
+35% +$14.3M
RARX
52
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$55.8M 0.38%
+1,188,100
New +$52.5M
CVS icon
53
CVS Health
CVS
$119B
$55.7M 0.38%
750,000
-150,000
-17% -$10.5M
MNTA
54
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$54.3M 0.37%
+2,750,000
New +$44M
SRPT icon
55
CALL
Sarepta Therapeutics
SRPT
$1.98B
$51.6M 0.35%
+400,000
New +$40.4M
ARQL
56
DELISTED
Arqule Inc
ARQL
$50.3M 0.34%
+2,520,000
New +$29.2M
AXSM icon
57
Axsome Therapeutics
AXSM
$10.9B
$45.7M 0.31%
442,222
+42,222
+11% +$1.71M
KRTX
58
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$45.2M 0.31%
+600,000
New +$26.3M
FATE icon
59
Fate Therapeutics
FATE
$279M
$44M 0.3%
2,250,000
– –
PGNX
60
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$42M 0.28%
8,250,000
+900,000
+12% +$4.76M
RDUS
61
DELISTED
Radius Health, Inc.
RDUS
$41.4M 0.28%
2,054,486
– –
TCDA
62
DELISTED
Tricida, Inc. Common Stock
TCDA
$37.7M 0.25%
1,000,000
+500,000
+100% +$18.6M
TVRD
63
Tvardi Therapeutics
TVRD
$24.8M
$37.1M 0.25%
63,889
+4,167
+7% +$2.92M
SAGE
64
DELISTED
Sage Therapeutics
SAGE
$36.1M 0.24%
500,000
+127,200
+34% +$15.6M
PTCT icon
65
PTC Therapeutics
PTCT
$5.83B
$34.9M 0.24%
726,986
– –
ZEAL
66
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$33.5M 0.23%
1,009,800
-200
-0% -$5.98K
MLNX
67
DELISTED
Mellanox Technologies, Ltd.
MLNX
$31.6M 0.21%
270,000
+145,000
+116% +$16.5M
TECX
68
Tectonic Therapeutic
TECX
$736M
$31.2M 0.21%
129,167
– –
TIF
69
DELISTED
Tiffany & Co.
TIF
$30.1M 0.2%
+225,000
New +$26.6M
INST
70
DELISTED
Instructure, Inc.
INST
$29.9M 0.2%
+620,000
New +$29.1M
NVTA
71
DELISTED
Invitae Corporation
NVTA
$28.2M 0.19%
1,750,000
+450,000
+35% +$7.96M
VCYT icon
72
Veracyte
VCYT
$3.4B
$27.9M 0.19%
1,000,000
– –
STML
73
DELISTED
Stemline Therapeutics, Inc.
STML
$25M 0.17%
2,350,000
+50,000
+2% +$496K
RC
74
Ready Capital
RC
$311M
$24.9M 0.17%
1,617,170
-587,962
-27% -$9.26M
QTNT
75
DELISTED
Quotient Limited Ordinary Shares
QTNT
$23.8M 0.16%
62,500
+20,000
+47% +$6.63M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2019 Portfolio in Review

As of Q4 2019, Thomas Steyer held 132 positions worth $14.8B, up 12% from $13.2B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Thomas Steyer withdrew a net $1.22B in Q4 2019, closing 16 positions and reducing 29 holdings. Its most notable exit was Celgene Corp, an estimated $1.55B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 45% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Salesforce worth $281M.

  • Thomas Steyer's largest Q4 2019 buy was Salesforce: 1,724,880 shares worth $281M.
  • Thomas Steyer added most to Allergan plc in Q4 2019, an estimated $317M increase.
  • Thomas Steyer's biggest Q4 2019 reduction was Broadmark Realty Capital Inc. Common Stock, cutting an estimated $754M.
  • Thomas Steyer fully exited Celgene Corp in Q4 2019, selling an estimated $1.55B.
  • Thomas Steyer's ten largest holdings make up 44% of its $14.8B portfolio in Q4 2019.
  • Thomas Steyer opened 32 new positions and closed 16 in Q4 2019.
  • Thomas Steyer's portfolio value rose 12% quarter-over-quarter to $14.8B.

Based on Farallon Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.